Business Wire

IDEO Appoints Design Luminary, Venture Innovator and IDEO Alumnus Michael Peng as Chief Executive Officer To Spearhead Growth

30.4.2025 19:00:00 CEST | Business Wire | Press Release

Share

IDEO, the global design company, announces the appointment of Michael Peng as its new Chief Executive Officer, effective June 2, 2025. Peng returns to the company after five years of transformative work at Moon Creative Lab, a venture studio established by global trading and investment company Mitsui & Co. His leadership will bring a unique blend of human-centered creativity, multicultural fluency, thoughtful collaboration, and strong business acumen.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430749502/en/

Mike Peng joins global design company IDEO as its next CEO in June 2025 (Photo: Business Wire)

Derek Robson, who has served as IDEO’s CEO since 2023, will move to a new group-level role focused on expanding collaboration within kyu, a collective of creative companies of which IDEO is a member. Robson’s work has reset IDEO’s foundation and primed the company for an exciting trajectory of growth. This timely transition sees design and venture pioneer Peng stepping in as the next CEO, a strategic appointment led by Robson.

“In Mike, we’ve found a leader whose brain, heart, courage, curiosity and design mastery make him the ideal match for IDEO’s evolving ambitions and an exceptional fit as the next Chief Executive Officer,” says Robson. “His return represents a reconnection with IDEO’s roots and a launchpad for its future. I’m looking forward to working with him.”

With a background in neuroscience, Peng is currently the Chief Creative Officer at Moon Creative Lab, where 11 ventures were successfully launched into the market. Prior to joining Moon, Peng was a Partner at IDEO. During his tenure of nearly 14 years at IDEO, he worked across diverse industries and global markets; fostered multicultural team collaboration; and helped establish the design research discipline in the New York office. He also opened and led IDEO Tokyo and co-founded D4V, Japan’s pioneering venture capital firm for early-stage startups.

Peng says: “I’m excited to be rejoining IDEO at a time when human-centeredness is needed more than ever in the technology-forward world that we live in. My most recent experiences in bringing new ventures to market have shown me the impact we can create in the world by utilizing emerging technologies through the lens of design. I’m eager to bring everyone together at IDEO to push the boundaries of design and help our clients and partners achieve market leadership and success.”

Michael Birkin, CEO of kyu adds, “Derek has restructured, stabilized, and explored new possibilities for IDEO. Now with Mike stepping into the role of CEO and Derek looking to unlock opportunity across kyu, IDEO is poised to accelerate its offerings, impact and growth.”

Commenting on the transition, David Kelley, co-founder of IDEO and Stanford University’s d.school, says: “I want to thank Derek for his dedication and look forward to the continued contributions he will make in his new capacity. Welcoming back Mike feels like a homecoming, and I’m thrilled to have him take the reins and shape what’s next for IDEO.”

For more information on this announcement, visit www.ideo.com/futurebydesign.

About IDEO

IDEO is a global design and innovation company. The company partners with organizations to tackle complex challenges, uncover new opportunities, and create meaningful and positive impact across business, society, and culture. From designing iconic products and services to crafting new ventures, to building creative capabilities within organizations, IDEO’s work is rooted in empathy and experimentation. Part of kyu, a collective of strategically curated creative organizations, IDEO has offices in the US, UK, and China. Learn more at www.ideo.com.

About Michael Peng

Michael Peng is a design and innovation leader who spent over a decade at IDEO (2006-2020), where he worked with a diverse range of Fortune 100 clients, helped grow IDEO’s global presence, co-founded the Tokyo studio, and launched D4V, Japan’s first early-stage design-focused venture fund. He became an IDEO Partner in 2017 and was appointed to the board of IDEO.org in 2020, a role he continues to hold. Mike is currently Chief Creative Officer at Moon Creative Lab, where he guides the development of new ventures and leads Moon Media, a storytelling initiative exploring creativity and entrepreneurship through film. A committed educator, he has taught at esteemed institutions including Copenhagen Institute of Interaction Design (CIID), New York University’s Robert F. Wagner Graduate School of Public Service, and The University of Tokyo. Mike holds a degree in cognitive science from the University of California, Berkeley.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250430749502/en/

Contacts

Media Contact
Kathryn Green
kgreen@ideo.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye